

Sabine Bahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9426851/publications.pdf>

Version: 2024-02-01

88
papers

3,523
citations

186265

28
h-index

155660

55
g-index

97
all docs

97
docs citations

97
times ranked

5756
citing authors

#	ARTICLE	IF	CITATIONS
1	mHealth Solutions for Perinatal Mental Health: Scoping Review and Appraisal Following the mHealth Index and Navigation Database Framework. <i>JMIR MHealth and UHealth</i> , 2022, 10, e30724.	3.7	13
2	The Current State and Validity of Digital Assessment Tools for Psychiatry: Systematic Review. <i>JMIR Mental Health</i> , 2022, 9, e32824.	3.3	12
3	The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets. <i>Npj Genomic Medicine</i> , 2022, 7, 25.	3.8	8
4	Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia. <i>Brain, Behavior, and Immunity</i> , 2022, 103, 37-49.	4.1	4
5	Novel open reading frames in human accelerated regions and transposable elements reveal new leads to understand schizophrenia and bipolar disorder. <i>Molecular Psychiatry</i> , 2022, 27, 1455-1468.	7.9	11
6	mHealth Solutions for Mental Health Screening and Diagnosis: A Review of App User Perspectives Using Sentiment and Thematic Analysis. <i>Frontiers in Psychiatry</i> , 2022, 13, 857304.	2.6	14
7	Using decision-analysis modelling to estimate the economic impact of the identification of unrecognised bipolar disorder in primary care: the untapped potential of screening. <i>International Journal of Bipolar Disorders</i> , 2022, 10, .	2.2	1
8	Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 673-682.	4.1	15
9	Building the Digital Mental Health Ecosystem: Opportunities and Challenges for Mobile Health Innovators. <i>Journal of Medical Internet Research</i> , 2021, 23, e27507.	4.3	14
10	The Current State and Diagnostic Accuracy of Digital Mental Health Assessment Tools for Psychiatric Disorders: Protocol for a Systematic Review and Meta-analysis. <i>JMIR Research Protocols</i> , 2021, 10, e25382.	1.0	10
11	Impact of a Web-Based Psychiatric Assessment on the Mental Health and Well-Being of Individuals Presenting With Depressive Symptoms: Longitudinal Observational Study. <i>JMIR Mental Health</i> , 2021, 8, e23813.	3.3	6
12	Toward an Extended Definition of Major Depressive Disorder Symptomatology: Digital Assessment and Cross-validation Study. <i>JMIR Formative Research</i> , 2021, 5, e27908.	1.4	1
13	Functional patient-derived cellular models for neuropsychiatric drug discovery. <i>Translational Psychiatry</i> , 2021, 11, 128.	4.8	7
14	Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial. <i>Schizophrenia Bulletin</i> , 2021, 47, 1108-1115.	4.3	24
15	The Delta Study – Prevalence and characteristics of mood disorders in 924 individuals with low mood: Results of the of the World Health Organization Composite International Diagnostic Interview (CIDI). <i>Brain and Behavior</i> , 2021, 11, e02167.	2.2	4
16	Proof-of-Concept Support for the Development and Implementation of a Digital Assessment for Perinatal Mental Health: Mixed Methods Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e27132.	4.3	12
17	Personality, symptom, and demographic correlates of perceived efficacy of selective serotonin reuptake inhibitor monotherapy among current users with low mood: A data-driven approach. <i>Journal of Affective Disorders</i> , 2021, 295, 1122-1130.	4.1	1
18	A machine learning algorithm to differentiate bipolar disorder from major depressive disorder using an online mental health questionnaire and blood biomarker data. <i>Translational Psychiatry</i> , 2021, 11, 41.	4.8	41

#	ARTICLE	IF	CITATIONS
19	Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment. <i>Schizophrenia Bulletin</i> , 2020, 46, 363-373.	4.3	46
20	Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks. <i>Molecular Psychiatry</i> , 2020, 25, 2355-2372.	7.9	22
21	Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	3
22	Denser brain capillary network with preserved pericytes in Alzheimer's disease. <i>Brain Pathology</i> , 2020, 30, 1071-1086.	4.1	19
23	Diagnostic prediction model development using data from dried blood spot proteomics and a digital mental health assessment to identify major depressive disorder among individuals presenting with low mood. <i>Brain, Behavior, and Immunity</i> , 2020, 90, 184-195.	4.1	12
24	Proteomic Profiling as a Diagnostic Biomarker for Discriminating Between Bipolar and Unipolar Depression. <i>Frontiers in Psychiatry</i> , 2020, 11, 189.	2.6	9
25	Spatial and temporal diversity of glycome expression in mammalian brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28743-28753.	7.1	67
26	A Combined Digital and Biomarker Diagnostic Aid for Mood Disorders (the Delta Trial): Protocol for an Observational Study. <i>JMIR Research Protocols</i> , 2020, 9, e18453.	1.0	18
27	Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia. <i>ACS Chemical Neuroscience</i> , 2019, 10, 58-78.	3.5	13
28	Integrating proteomic, sociodemographic and clinical data to predict future depression diagnosis in subthreshold symptomatic individuals. <i>Translational Psychiatry</i> , 2019, 9, 277.	4.8	10
29	Converging evidence points towards a role of insulin signaling in regulating compulsive behavior. <i>Translational Psychiatry</i> , 2019, 9, 225.	4.8	20
30	Increased serum levels of leptin and insulin in both schizophrenia and major depressive disorder: A cross-disorder proteomics analysis. <i>European Neuropsychopharmacology</i> , 2019, 29, 835-846.	0.7	26
31	Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo. <i>Science Advances</i> , 2019, 5, eaau9093.	10.3	22
32	Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment. <i>JAMA Psychiatry</i> , 2019, 76, 864.	11.0	43
33	Multimodel inference for biomarker development: an application to schizophrenia. <i>Translational Psychiatry</i> , 2019, 9, 83.	4.8	17
34	Proteomic approaches to identify blood-based biomarkers for depression and bipolar disorders. <i>Expert Review of Proteomics</i> , 2018, 15, 325-340.	3.0	30
35	Virus discovery analyses on post-mortem brain tissue and cerebrospinal fluid of schizophrenia patients. <i>Schizophrenia Research</i> , 2018, 197, 605-606.	2.0	6
36	Allostatic load is associated with psychotic symptoms and decreases with antipsychotic treatment in patients with schizophrenia and first-episode psychosis. <i>Psychoneuroendocrinology</i> , 2018, 90, 35-42.	2.7	47

#	ARTICLE	IF	CITATIONS
37	Evaluation of molecular brain changes associated with environmental stress in rodent models compared to human major depressive disorder: A proteomic systems approach. <i>World Journal of Biological Psychiatry</i> , 2018, 19, S63-S74.	2.6	8
38	Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 129-143.	3.2	45
39	Evidence of microglial activation following exposure to serum from first-onset drug-naïve schizophrenia patients. <i>Brain, Behavior, and Immunity</i> , 2018, 67, 364-373.	4.1	17
40	Temporal proteomic profiling of postnatal human cortical development. <i>Translational Psychiatry</i> , 2018, 8, 267.	4.8	22
41	Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment. <i>PLoS ONE</i> , 2018, 13, e0192278.	2.5	5
42	Lithium reverses behavioral and axonal transport-related changes associated with ANK3 bipolar disorder gene disruption. <i>European Neuropsychopharmacology</i> , 2017, 27, 274-288.	0.7	20
43	Towards reproducible MRM based biomarker discovery using dried blood spots. <i>Scientific Reports</i> , 2017, 7, 45178.	3.3	30
44	Alteration of Neuronal Excitability and Short-Term Synaptic Plasticity in the Prefrontal Cortex of a Mouse Model of Mental Illness. <i>Journal of Neuroscience</i> , 2017, 37, 4158-4180.	3.6	64
45	Associations between SNPs and immune-related circulating proteins in schizophrenia. <i>Scientific Reports</i> , 2017, 7, 12586.	3.3	21
46	Schizophrenia-risk and urban birth are associated with proteomic changes in neonatal dried blood spots. <i>Translational Psychiatry</i> , 2017, 7, 1290.	4.8	30
47	A brain proteomic investigation of rapamycin effects in the <i>Tsc1</i> +/Δ mouse model. <i>Molecular Autism</i> , 2017, 8, 41.	4.9	19
48	Neuroimmune biomarkers in schizophrenia. <i>Schizophrenia Research</i> , 2016, 176, 3-13.	2.0	109
49	Sex Differences in Serum Markers of Major Depressive Disorder in the Netherlands Study of Depression and Anxiety (NESDA). <i>PLoS ONE</i> , 2016, 11, e0156624.	2.5	54
50	Molecular serum signature of treatment resistant depression. <i>Psychopharmacology</i> , 2016, 233, 3051-3059.	3.1	20
51	Cell Type-Specific Effects of Mutant DISC1: A Proteomics Study. <i>Molecular Neuropsychiatry</i> , 2016, 2, 28-36.	2.9	8
52	Blood-based immune-endocrine biomarkers of treatment response in depression. <i>Journal of Psychiatric Research</i> , 2016, 83, 249-259.	3.1	24
53	Variation in serum biomarkers with sex and female hormonal status: implications for clinical tests. <i>Scientific Reports</i> , 2016, 6, 26947.	3.3	30
54	Proteomic systems evaluation of the molecular validity of preclinical psychosis models compared to schizophrenia brain pathology. <i>Schizophrenia Research</i> , 2016, 177, 98-107.	2.0	13

#	ARTICLE	IF	CITATIONS
55	Synaptic vesicle dynamic changes in a model of fragile X. <i>Molecular Autism</i> , 2016, 7, 17.	4.9	21
56	Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. <i>Brain, Behavior, and Immunity</i> , 2016, 52, 178-186.	4.1	26
57	Towards a blood-based diagnostic panel for bipolar disorder. <i>Brain, Behavior, and Immunity</i> , 2016, 52, 49-57.	4.1	59
58	Shared Immune and Repair Markers During Experimental <i>Toxoplasma</i> Chronic Brain Infection and Schizophrenia. <i>Schizophrenia Bulletin</i> , 2016, 42, 386-395.	4.3	18
59	The association between antibodies to neurotropic pathogens and schizophrenia: a case-control study. <i>NPJ Schizophrenia</i> , 2015, 1, 15041.	3.6	29
60	Immunomodulatory Effects of Probiotic Supplementation in Schizophrenia Patients: A Randomized, Placebo-Controlled Trial. <i>Biomarker Insights</i> , 2015, 10, BMI.S22007.	2.5	109
61	Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia. <i>Proteomics - Clinical Applications</i> , 2015, 9, 907-916.	1.6	21
62	Association of DNA Methylation with Acute Mania and Inflammatory Markers. <i>PLoS ONE</i> , 2015, 10, e0132001.	2.5	28
63	Hippocampal Proteomic and Metabonomic Abnormalities in Neurotransmission, Oxidative Stress, and Apoptotic Pathways in a Chronic Phencyclidine Rat Model. <i>Journal of Proteome Research</i> , 2015, 14, 3174-3187.	3.7	14
64	Proteomic Enrichment Analysis of Psychotic and Affective Disorders Reveals Common Signatures in Presynaptic Glutamatergic Signaling and Energy Metabolism. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, .	2.1	44
65	Commercialisation of Biomarker Tests for Mental Illnesses: Advances and Obstacles. <i>Trends in Biotechnology</i> , 2015, 33, 712-723.	9.3	19
66	What Can We Learn About Depression from Gene Expression in Peripheral Tissues?. <i>Biological Psychiatry</i> , 2015, 77, 207-209.	1.3	9
67	Multiplex immunoassay analysis of plasma shows differences in biomarkers related to manic or mixed mood states in bipolar disorder patients. <i>Journal of Affective Disorders</i> , 2015, 185, 12-16.	4.1	14
68	Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank: Figure 1.. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv042.	2.1	84
69	Targeted Multiplexed Selected Reaction Monitoring Analysis Evaluates Protein Expression Changes of Molecular Risk Factors for Major Psychiatric Disorders. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, .	2.1	36
70	Distinct proteomic profiles in post-mortem pituitary glands from bipolar disorder and major depressive disorder patients. <i>Journal of Psychiatric Research</i> , 2015, 60, 40-48.	3.1	31
71	Proteomic changes in serum of first onset, antidepressant drug-naïve major depression patients. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1599-1608.	2.1	91
72	The need for a comprehensive molecular characterization of autism spectrum disorders. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 651-673.	2.1	13

#	ARTICLE	IF	CITATIONS
73	Technological advances for deciphering the complexity of psychiatric disorders: merging proteomics with cell biology. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1327-1341.	2.1	10
74	Identification of Subgroups of Schizophrenia Patients With Changes in Either Immune or Growth Factor and Hormonal Pathways. <i>Schizophrenia Bulletin</i> , 2014, 40, 787-795.	4.3	84
75	Serum proteomic analysis identifies sex-specific differences in lipid metabolism and inflammation profiles in adults diagnosed with Asperger syndrome. <i>Molecular Autism</i> , 2014, 5, 4.	4.9	57
76	Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. <i>Schizophrenia Research</i> , 2014, 154, 23-29.	2.0	171
77	Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. <i>Progress in Neurobiology</i> , 2014, 122, 45-72.	5.7	77
78	Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16136-16141.	7.1	545
79	Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders. <i>Molecular Autism</i> , 2014, 5, 38.	4.9	33
80	Proteomic analysis of post mortem brain tissue from autism patients: evidence for opposite changes in prefrontal cortex and cerebellum in synaptic connectivity-related proteins. <i>Molecular Autism</i> , 2014, 5, 41.	4.9	63
81	Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3 β signaling in bipolar patients. <i>Journal of Affective Disorders</i> , 2014, 156, 139-143.	4.1	30
82	Proteomics: improving biomarker translation to modern medicine?. <i>Genome Medicine</i> , 2013, 5, 17.	8.2	27
83	Identification of altered dipeptidyl-peptidase activities as potential biomarkers for unipolar depression. <i>Journal of Affective Disorders</i> , 2013, 151, 667-672.	4.1	16
84	Schizophrenia: Metabolic aspects of aetiology, diagnosis and future treatment strategies. <i>Psychoneuroendocrinology</i> , 2013, 38, 752-766.	2.7	93
85	Proteomic profiling in schizophrenia: enabling stratification for more effective treatment. <i>Genome Medicine</i> , 2013, 5, 25.	8.2	19
86	Challenges of Introducing New Biomarker Products for Neuropsychiatric Disorders into the Market. <i>International Review of Neurobiology</i> , 2011, 101, 299-327.	2.0	18
87	Gene expression in the prefrontal cortex during adolescence: implications for the onset of schizophrenia. <i>BMC Medical Genomics</i> , 2009, 2, 28.	1.5	97
88	Transcriptional neoteny in the human brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5743-5748.	7.1	347